You are here
Annual overview
16 April 2008: Issuers of listed transferable securities are required to provide Oslo Børs with an annual statement of information made available to the public, cf the Securities Trading Act section 5-11 first subsection. Attached to www.newsweb.no is an annual overview for NorDiag ASA.
Contact:
CEO Mårten Wigstøl, phone 911 65775
or
CFO Tone Kvåle, phone 915 19576.
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com
Link to the Stock Exchange Notification with attached annual overview